載入中
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
前收盤價
US$6.07
−US$0.02 · -0.33%
盤前
US$6.06
−US$0.01 · -0.16%
10月8日 上午9:04 ET
盤中時間採用ET。市場資料可能有所延遲。
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
日內區間
目前US$6.07
52週區間
目前US$6.07
盤中時間採用ET。市場資料可能有所延遲。
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
日內區間
目前US$6.07
52週區間
目前US$6.07
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | — | 57.42萬 USD | 29.42萬 USD |
| 毛利 | — | — | — | 57.42萬 USD | 29.42萬 USD |
| 研究與開發 | 191.2萬 USD | 221.2萬 USD | 252萬 USD | 274.5萬 USD | 234.1萬 USD |
| 銷售、一般及管理費用 | 729.36萬 USD | 934.14萬 USD | 1263.66萬 USD | 1247.29萬 USD | 1071.51萬 USD |
| 營業費用 | 729.36萬 USD | 934.14萬 USD | 1263.66萬 USD | 1247.29萬 USD | 1071.51萬 USD |
| 利息收入 | 15.65萬 USD | 29.81萬 USD | 42.84萬 USD | 1.1萬 USD | — |
| 利息支出 | 1.44萬 USD | 1.01萬 USD | — | — | — |
| 折舊和攤銷 | 32.37萬 USD | 33.96萬 USD | 35.91萬 USD | 24.09萬 USD | 12.37萬 USD |
| 營業利益 | −729.36萬 USD | −934.14萬 USD | −1263.66萬 USD | −1189.86萬 USD | −1042.09萬 USD |
| 淨利 | −715.15萬 USD | −1338.81萬 USD | −1220.82萬 USD | −1202.98萬 USD | −1041.61萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$1.50
下跌空間 75.29%評級樣本有限，僅3項
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年8月4日 | 1:5 | — | — |
股票分割 | 2025年10月20日 | 1:10 | — | — |
股票分割 | 2025年6月9日 | 1:8 | — | — |
股票分割 | 2023年10月5日 | 1:10 | — | — |
股票分割 | 2019年10月15日 | 1:15 | — | — |
股票分割 | 2015年4月14日 | 1:50 | — | — |
已生效 2026年8月4日
1:5
已生效 2025年10月20日
1:10
已生效 2025年6月9日
1:8
已生效 2023年10月5日
1:10
已生效 2019年10月15日
1:15
已生效 2015年4月14日
1:50
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
